Company Filing History:
Years Active: 1990
Title: Gary W. Whitaker: Innovator in Macrolide Antibiotics
Introduction
Gary W. Whitaker is a notable inventor based in Indianapolis, IN (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of novel macrolide antibiotics. His work focuses on treating infections caused by pathogenic bacteria, especially Gram-positive bacteria.
Latest Patents
Gary W. Whitaker holds a patent for a Dirithromycin metabolite. This novel macrolide, known as AS-E 136 metabolite, is obtained from the body fluids of animals receiving AS-E 136 or erythromycylamine. The patent outlines methods for treating infections caused by pathogenic bacteria and pharmaceutical compositions containing the metabolite.
Career Highlights
Whitaker is associated with Eli Lilly and Company, a leading pharmaceutical firm known for its innovative research and development. His work at Eli Lilly has allowed him to contribute to advancements in antibiotic therapies.
Collaborations
One of his notable coworkers is Terry D. Lindstrom, with whom he has collaborated on various projects related to antibiotic development.
Conclusion
Gary W. Whitaker's contributions to the field of macrolide antibiotics highlight his innovative spirit and dedication to improving healthcare. His patent for the Dirithromycin metabolite represents a significant advancement in the treatment of bacterial infections.